Celldex Therapeutics - CLDX Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CLDX shares.
View CLDX analyst ratings or view top-rated stocks.

3 Wall Street analysts have issued 12-month price targets for Celldex Therapeutics' stock. Their CLDX share price forecasts range from $63.00 to $73.00. On average, they expect the company's share price to reach $66.67 in the next twelve months. This suggests a possible upside of 89.4% from the stock's current price.
View analysts price targets for CLDX or view top-rated stocks among Wall Street analysts.

Celldex Therapeutics' stock was trading at $44.57 on January 1st, 2023. Since then, CLDX stock has decreased by 21.0% and is now trading at $35.20.
View the best growth stocks for 2023 here.

Celldex Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 3,820,000 shares, an increase of 5.5% from the February 28th total of 3,620,000 shares. Based on an average daily volume of 477,300 shares, the short-interest ratio is currently 8.0 days.
View Celldex Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our CLDX earnings forecast.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by $0.09. The biopharmaceutical company earned $0.15 million during the quarter, compared to the consensus estimate of $1.70 million. Celldex Therapeutics had a negative trailing twelve-month return on equity of 28.90% and a negative net margin of 4,765.59%.

ETFs with the largest weight of Celldex Therapeutics (NASDAQ:CLDX) stock in their portfolio include Alger Mid Cap 40 ETF (FRTY), ALPS Medical Breakthroughs ETF (SBIO), Invesco DWA Healthcare Momentum ETF (PTH), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC) and iShares Micro-Cap ETF (IWC).

Shares of Celldex Therapeutics reverse split before market open on Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 8th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Celldex Therapeutics investors own include OPKO Health (OPK), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP), Precigen (PGEN), Micron Technology (MU), Dynavax Technologies (DVAX), Exelixis (EXEL), bluebird bio (BLUE) and SCYNEXIS (SCYX).

Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."

Celldex Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Jennison Associates LLC (3.30%), Geode Capital Management LLC (1.88%), Price T Rowe Associates Inc. MD (1.77%), Marshall Wace LLP (1.42%), Eversept Partners LP (1.19%) and Fred Alger Management LLC (1.11%). Insiders that own company stock include Anthony S Marucci, Diane C Young, Elizabeth Crowley, Freddy A Jimenez, James J Marino, Margo Heath-Chiozzi, Richard M Wright, Samuel Bates Martin, Sarah Cavanaugh and Tibor Keler.
View institutional ownership trends.

Shares of CLDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CLDX stock can currently be purchased for approximately $35.20.

Celldex Therapeutics (NASDAQ:CLDX) has a market capitalization of $1.66 billion and generates $2.36 million in revenue each year. The biopharmaceutical company earns $-112,320,000.00 in net income (profit) each year or ($2.39) on an earnings per share basis.

The company employs 132 workers across the globe.

Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The official website for the company is www.celldex.com. The biopharmaceutical company can be reached via phone at (908) 454-7120, via email at ir@celldextherapeutics.com, or via fax at 908-454-1911.